Gliknik Inc.

Gliknik is a development stage innovative research company creating new drugs for autoimmune diseases and cancer. Two peptide immune modulators are in dose rising studies in patients with advanced Head and Neck Squamous Cell Carcinoma. A lead compound is in pre-clinical development in the stradomer IVIG-mimetic program. Gliknik is also conducting research on stradobodiesTM, modified monoclonal antibodies for cancer.